New Medicines of 2015
Imlygic is a prescription drug used to treat melanoma lesions on the skin and in the lymph nodes. Melanoma is the most dangerous skin cancer. Imlygic belongs to a group of drugs called oncolytic viruses, which work by replicating inside cancer cells, causing the cells to burst and die. This medication is directly injected into melanoma lesions. Common side effects include fatigue, chills, nausea, flu-like symptoms, injection site pain and fever. Imlygic is a first-of-its-kind treatment for melanoma.
1/15
Reviewed by:
Review Date:
December 29, 2015Citation:
U.S. Food and Drug Administration, "FDA approves first-of-its-kind product for the treatment of melanoma", 2015 U.S. Food and Drug Administration, "FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa", 2015 U.S. Food and Drug Administration, "FDA approves Ninlaro, new oral medication to treat multiple myeloma", 2015 U.S. Food and Drug Administration, "FDA approves new treatment for HIV", 2015 U.S. Food and Drug Administration, "FDA approves Nucala to treat severe asthma", 2015 U.S. Food and Drug Administration, "FDA approves new treatment for advanced pancreatic cancer", 2015 U.S. Food and Drug Administration, "FDA approves first treatment for sexual desire disorder", 2015 U.S. Food and Drug Administration, "FDA approves new drug to treat heart failure", 2015 U.S. Food and Drug Administration, "FDA approves Praluent to treat certain patients with high cholesterol", 2015 U.S. Food and Drug Administration, "FDA approves Corlanor to treat heart failure", 2015 All images appear courtesy of Dreamstime
Last Updated:
December 29, 2015